Abemaciclib
FDA-approved product (tablet, oral), marketed as Verzenio.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- HER2 Positive Breast Carcinoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Cyclin-dependent kinase (cdk) inhibitors
- FDA pharmacologic class
- Kinase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Abemaciclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT06062498 · start 2023-09-29
Registered record
- Registry ID
- NCT06062498
- Conditions
- Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer
- Interventions
- elacestrant, palbociclib, abemaciclib, ribociclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-09-29
- Completion
- 2029-07-01
- Enrolment
- 174
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEstrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast CancerInterventionelacestrant, palbociclib, abemaciclib, ribociclibPhasePhase 2Registry statusRecruitingEffect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer
NCT06152471 · start 2023-06-07
Registered record
- Registry ID
- NCT06152471
- Conditions
- Early-stage Breast Cancer; Diarrhea; Adverse Drug Event
- Interventions
- SPC-flakes; Salovum; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2023-06-07
- Completion
- 2025-03-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEarly-stage Breast Cancer; Diarrhea; Adverse Drug EventInterventionSPC-flakes; Salovum; PlaceboPhasePhase 3Registry statusUnknownAbemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 · start 2023-05-20
Registered record
- Registry ID
- NCT06344780
- Conditions
- Breast Cancer
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2023-05-20
- Completion
- 2025-02-01
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionNot recordedPhaseNot recordedRegistry statusUnknownImplantable Microdevice for TNBC - Pilot Study
NCT05774886 · start 2023-05
Registered record
- Registry ID
- NCT05774886
- Conditions
- Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma
- Interventions
- Implantable Microdevice (IMD)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2023-05
- Completion
- 2028-09-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTriple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer +3 moreInterventionImplantable Microdevice (IMD)PhasePhase 1Registry statusWithdrawnOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080 · start 2023-03-28
Registered record
- Registry ID
- NCT05735080
- Conditions
- Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer
- Interventions
- INX-315; Fulvestrant; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2023-03-28
- Completion
- 2027-09
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast +5 moreInterventionINX-315; Fulvestrant; AbemaciclibPhasePhase 1 / Phase 2Registry statusRecruitingTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127 · start 2023-02-23
Registered record
- Registry ID
- NCT05548127
- Conditions
- Breast Cancer
- Interventions
- ARV-471; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Active not recruiting
- Start
- 2023-02-23
- Completion
- 2027-03-24
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionARV-471; AbemaciclibPhasePhase 1 / Phase 2Registry statusActive not recruitingA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072 · start 2023-01-25
Registered record
- Registry ID
- NCT05714072
- Conditions
- Myelofibrosis Due to and Following Polycythemia Vera
- Interventions
- Ruxolitinib; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Recruiting
- Start
- 2023-01-25
- Completion
- 2027-01
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelofibrosis Due to and Following Polycythemia VeraInterventionRuxolitinib; AbemaciclibPhasePhase 1Registry statusRecruitingStudy of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108 · start 2022-08-31
Registered record
- Registry ID
- NCT05386108
- Conditions
- Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases
- Interventions
- Elacestrant; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2022-08-31
- Completion
- 2026-12
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms +4 moreInterventionElacestrant; AbemaciclibPhasePhase 1 / Phase 2Registry statusRecruitingAnastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT05524584 · start 2022-08-31
Registered record
- Registry ID
- NCT05524584
- Conditions
- Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
- Interventions
- Fulvestrant; Anastrozole; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2022-08-31
- Completion
- 2031-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast CancerInterventionFulvestrant; Anastrozole; AbemaciclibPhasePhase 2Registry statusRecruitingAbemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
NCT05789771 · start 2022-04-01
Registered record
- Registry ID
- NCT05789771
- Conditions
- HR+/HER2- Breast Cancer; Metastatic Disease; Аdvanced Disease
- Interventions
- Abemaciclib; Abemaciclib; Abemaciclib
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2022-04-01
- Completion
- 2022-12-01
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHR+/HER2- Breast Cancer; Metastatic Disease; Аdvanced DiseaseInterventionAbemaciclib; Abemaciclib; AbemaciclibPhaseNot recordedRegistry statusCompletedA Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults
NCT05189717 · start 2022-02-17
Registered record
- Registry ID
- NCT05189717
- Conditions
- Metastatic or Local Advanced Breast Cancer of Patients
- Interventions
- HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2022-02-17
- Completion
- 2025-07-31
- Enrolment
- 156
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic or Local Advanced Breast Cancer of PatientsInterventionHRS-8080 tablets、SHR 6390 tablets、Abemaciclib、EverolimusPhasePhase 1Registry statusUnknownAbemaciclib With or Without Atezolizumab for mCRPC
NCT04751929 · start 2021-08-20
Registered record
- Registry ID
- NCT04751929
- Conditions
- Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
- Interventions
- Abemaciclib; Atezolizumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-08-20
- Completion
- 2025-11-06
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Metastatic Castration-resistant Prostate CancerInterventionAbemaciclib; AtezolizumabPhasePhase 2Registry statusCompletedImmune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
NCT04169074 · start 2021-07-07
Registered record
- Registry ID
- NCT04169074
- Conditions
- HNSCC
- Interventions
- Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2021-07-07
- Completion
- 2025-01-13
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHNSCCInterventionAbemaciclibPhasePhase 2Registry statusTerminatedPreOperative Endocrine Therapy for Individualised Care With Abemaciclib
NCT04584853 · start 2020-12-23
Registered record
- Registry ID
- NCT04584853
- Conditions
- Breast Cancer Female
- Interventions
- Abemaciclib; Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2020-12-23
- Completion
- 2030-10
- Enrolment
- 123
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer FemaleInterventionAbemaciclib; Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)PhasePhase 3Registry statusActive not recruitingLY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT04616183 · start 2020-12-02
Registered record
- Registry ID
- NCT04616183
- Conditions
- Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectabl
- Interventions
- Abemaciclib; Cetuximab; ERK1/2 Inhibitor LY3214996
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-12-02
- Completion
- 2028-12-31
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma +26 moreInterventionAbemaciclib; Cetuximab; ERK1/2 Inhibitor LY3214996PhasePhase 1 / Phase 2Registry statusActive not recruiting